argenx NV ADR (ARGX)
NASDAQ · Healthcare · Biotechnology
argenx NV ADR is a Healthcare company with a market capitalization of $55.44B and a trailing P/E ratio of 39.4.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $4.70 | $4.19 | +12.2% |
| Q4 2025 | February 26, 2026 | $6.79 | $5.95 | +14.2% |
| Q3 2025 | October 30, 2025 | $4.44 | $3.54 | +25.4% |
| Q2 2025 | July 31, 2025 | $3.26 | $2.61 | +24.9% |
| Q1 2025 | May 8, 2025 | $2.27 | $2.05 | +10.7% |
| Q4 2024 | March 31, 2025 | $0.71 | $1.70 | -58.0% |
Other Biotechnology Stocks
Frequently Asked Questions
What is argenx NV ADR's market cap?
As of June 29, 2026, argenx NV ADR (ARGX) has a market capitalization of $55.44B.
What is argenx NV ADR's P/E ratio?
argenx NV ADR trades at a trailing price-to-earnings (P/E) ratio of 39.4. Its forward P/E is 34.0.
Does argenx NV ADR pay a dividend?
argenx NV ADR does not currently pay a dividend.
What sector is ARGX in?
argenx NV ADR is in the Healthcare sector, specifically the Biotechnology industry.
What was argenx NV ADR's revenue?
In its latest reported fiscal year (ending December 31, 2025), argenx NV ADR reported revenue of $4.15B and net income of $1.29B.
Ask your own questions about ARGX
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.